Skip to content

Effect of Sequential Use of SanJieZhenTong Capsule and Gonadotropin-releasing Hormone Agonist for endomtriosis After Conservative Surgery: A Prospective Multi-Center Randomized Trial

Effect of Sequential Use of SanJieZhenTong Capsule and Gonadotropin-releasing Hormone Agonist for endomtriosis After Conservative Surgery: A Prospective Multi-Center Randomized Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17013692
Enrollment
Unknown
Registered
2017-12-05
Start date
2017-12-15
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

1:GnRH Injection
2:Sanjiezhentong Capsule
3:OC

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Women with stage III to IV of endometriosis confirmed by operation, who were within 18-45 years old, and received the conservative surgery; (2) Informed consent was signed; (3) No birth plan within one year; (4) Women should be able to express their complaints and answers to symptoms in well mental and physical state.

Exclusion criteria

Exclusion criteria: (1) Patients who suffer gynecologic malignant tumor, genital tubercle, or those endometriosis patients who had underwent total hysterectomy with bilateral salpingo-oophorectomy; (2) Patients who suffer together with other internal diseases, like cardiovascular, hepatic, renal, or hematopoietic disease; (3) Combined with other gynecological endocrine diseases, such as PCOS; (4) Pregnancies or lactation; or patients who are allergic to the experimental drug; or those who have participated in other clinical trials; (5) Hb<80g/L; (6) Patients with the family history of thrombosis or thrombotic disease.

Design outcomes

Primary

MeasureTime frame
VAS score;QOL;pelvic lesion;Recurrence Rate;

Secondary

MeasureTime frame
Ovarian Function;QALY;CA125;pregnancy rate;

Countries

China

Contacts

Public ContactCongjian Xu

Obstetrics and Gynecology Hospital of Fudan University

xucj@hotmail.com+86 13651796353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026